- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Why Vincerx Pharma (VINC) Stock Is Falling | 4 | Benzinga.com | ||
| Fr | Vincerx Pharma dips 16%, prices $16M stock | 2 | Seeking Alpha | ||
| Fr | Vincerx Pharma, Inc.: Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants | 2 | GlobeNewswire (USA) | ||
| Do | Vincerx Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Vincerx Pharma announces proposed underwritten public offering of common stock and warrants | 2 | Seeking Alpha | ||
| 09.04. | Vincerx (VINC) Tumbles on Results From Cancer Therapy Study | 6 | Zacks | ||
| 09.04. | Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday? | 3 | Benzinga.com | ||
| 09.04. | Why Is Vincerx Pharma (VINC) Stock Down 64% Today? | 3 | InvestorPlace | ||
| 09.04. | Vincerx in selloff after early-stage data for cancer therapy | 6 | Seeking Alpha | ||
| 09.04. | Vincerx Pharma tumbles as cancer therapy study data comes in below expectations | 4 | Reuters | ||
| 08.04. | Vincerx Pharma, Inc.: Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 | 68 | GlobeNewswire (Europe) | VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic... ► Artikel lesen | |
| 08.04. | Vincerx Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.04. | Check-Cap, Outset Medical, Vincerx Pharma among healthcare movers | 6 | Seeking Alpha | ||
| 01.04. | Vincerx Pharma GAAP EPS of -$0.23 beats by $0.06 | 1 | Seeking Alpha | ||
| 29.03. | Vincerx Pharma Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 29.03. | Vincerx Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.03. | Vincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update | 194 | GlobeNewswire (Europe) | VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00... ► Artikel lesen | |
| 29.03. | Vincerx Pharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Vincerx Pharma, Inc.: Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 | 7 | GlobeNewswire (USA) | ||
| 16.01. | Vincerx Pharma, Inc. - 8-K, Current Report | 4 | SEC Filings |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 9,000 | +7,14 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| ROCKET LAB USA | 3,510 | -0,28 % | How Rocket Lab Outgrew Billionaire Elon Musk's Space Company in Q1 | ||
| BOIRON | 34,150 | +1,49 % | BOIRON: Outlook 2023 - Communication calendar 2024 | The Board of Directors of Laboratoires BOIRON met on 19 December 2023, under the chairmanship of Mr Thierry Boiron.
At this meeting, the Board reviewed the latest business and earnings forecasts... ► Artikel lesen | |
| MEDICINOVA | 1,250 | 0,00 % | MediciNova, Inc.: MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) | LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 6,080 | -0,65 % | Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders | SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,080 | +3,82 % | Aquestive wins FDA approval for anti-seizure therapy Libervant | ||
| HARROW | 10,530 | +5,30 % | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen | |
| SHINECO | 0,810 | +1,39 % | Shineco, Inc.: Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement | BEIJING, March 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that... ► Artikel lesen | |
| CYANOTECH | 0,260 | 0,00 % | Delisting of Securities of NanoString Technologies, Inc.; Remark Holdings, Inc.; Sunworks, Inc.; Cyanotech Corporation; Sientra, Inc.; Charge Enterprises, Inc. and others from The Nasdaq Stock Market | NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of NanoString Technologies, Inc. NanoString Technologies, Inc.'s securities... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 1,760 | +7,65 % | Cumberland Pharmaceuticals Inc.: Cumberland Pharmaceuticals Reports Annual 2023 Financial Results | 2023 highlights include expanded FDA approval and new study publications
NASHVILLE, Tenn., March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 2,990 | +0,34 % | Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia | - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)... ► Artikel lesen | |
| BAYER | 27,400 | +1,88 % | Keine Dividende bei TUI, Tesla ruft Cybertrucks zurück, Bayer ohne neue Impulse und Varta wird von Anlegern sehr kritisch beäugt | Es gibt so einige Faktoren, die an der Börse Voraussetzung für steigende Kurse sind. Dazu gehören beispielsweise Fundamentalindikatoren und die Prognosen der Analysten. Doch die Grundvoraussetzung für... ► Artikel lesen | |
| MERCK KGAA | 151,75 | +1,10 % | Große Kursgewinne für den Anteilsschein von Merck (153,30 €) | Am deutschen Aktienmarkt brilliert derzeit der Anteilsschein von Merck . Das Papier steigt deutlich. Die Aktie von Merck gehört heute mit einem Kursplus von 3,79 Prozent zu den Gewinnern des Tages.... ► Artikel lesen | |
| CANOPY GROWTH | 8,370 | +0,48 % | Spotlight on Canopy Growth: Analyzing the Surge in Options Activity | ||
| NOVO NORDISK | 119,12 | +2,51 % | Goldene Zeiten nicht nur für Novo Nordisk und Eli Lilly? Diese Aktien könnten bald extrem steigen | Bei Unternehmen aus der Biotech- und Pharmaindustrie herrscht gerade Goldgräberstimmung. Davon profitieren nicht nur Größen wie Novo Nordisk und Eli Lilly. Der Hype ist unglaublich und wohl noch lange... ► Artikel lesen |
VINCERX PHARMA INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -18,59 % bei einem Aktienkurs von 0,730 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
